$AVEO,,,Additional Info.: AVEO Pharmaceuticals
Post# of 22755
AVEO Pharmaceuticals
AVEO managed to stay near the top of the list for a second week in a row, this pharmaceutical is working on cancer candidate treatments. Last week the company announced it had secured a $14 million in aggregate gross proceeds from its credit facility.
“AVEO now has resources that we expect will take us well past the anticipated first quarter 2018 readout of the TIVO-3 trial, our U.S. pivotal trial in third-line RCC,” Michael Bailey, president and CEO of AVEO said in a statement.
AVEO Pharmaceuticals gained 74.4 percent last week and traded at $2.17 per share.
https://twitter.com/twitter/statuses/957208055766241280